By
Drug Target Review2025-02-13T08:00:56
An AI tool has identified adalimumab, a drug used for arthritis and Crohn’s disease, as a life-saving treatment for rare Castleman’s disease (iMCD). This finding offers hope for patients with the condition.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-12T09:31:00Z
Contributor Sugish Pillai, Axel Ziemke and Dr Gary Kusdian
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-03-20T13:41:33
Sponsored by Bio-Techne
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2026-05-12T09:31:00
Contributor Sugish Pillai, Axel Ziemke and Dr Gary Kusdian
2025-09-18T12:00:00
Sponsored by Benchling
2026-06-24T13:00:00 2026-06-24T14:00:00
Sponsored by HUB Organoids
Site powered by Webvision Cloud